Corporate Bond Sales Surpass $3 Trillion on Low Yields
Corporate bond sales worldwide totaled $3.19 trillion this year, as companies took advantage of the lowest yields on record.
Johnson Johnson
Johnson & Johnson Announces Bid for Crucell
As part of its efforts to expand into the biotech market, Johnson & Johnson is making a long-anticipated bid for Dutch vaccine maker Crucell -- in spite of Crucell's recent manufacturing troubles.
Can GE and J&J Help Detect Alzheimer's Earlier?
Medical imaging and diagnostics powerhouse GE Healthcare teams up with pharmaceutical giant Johnson & Johnson to research methods of detecting Alzheimer's in patients -- even before they begin to exhibit symptoms of the devastating disease.
Big in Japan: Johnson & Johnson's Contact Lens Recall
Johnson & Johnson expanded its recall of Acuvue TruEye contact lenses fivefold back in October, but only announced the news in Japan, where most of the recalled lenses were sold.
Johnson & Johnson CEO to Apologize for Recalls
CEO William Weldon will apologize to Congress for a series of product recalls over the past year. The company is also expected to resume shipments of children's cold medication next week.
Was Johnson & Johnson aware of problems with its Children's Tylenol months before the recall? The House Oversight Committee has invited an FDA commissioner and Johnson & Johnson chairman to a hearing next week to address this and other questions surrounding the massive recall of children's medicines earlier this year.
Johnson & Johnson's Latest Recall: Acuvue Contact Lenses
Johnson & Johnson's quality-control troubles apparently aren't over yet. The company on Monday recalled millions of 1 Day Acuvue contact lenses, marking its ninth consumer-product recall in a year.
Johnson & Johnson Fights Charges of Recalls and Kickbacks
Johnson & Johnson shares are rebounding as the drug maker recovers from federal charges it paid kickbacks to a pharmacy company to boost sales of its drugs to nursing-home patients. Meantime, the Food and Drug Administration accused it of being too slow with its product recall during a Tylenol scare.
Good Results for Celgene's Cancer Drug
Drug maker Celgene (CELG) says its multiple myeloma cancer pill reduced the risk of progression by half among newly diagnosed patients who used the drug and chemotherapy compared with those who only used chemotherapy.
